Sarepta Therapeutics (NASDAQ:SRPT) Trading 5.3% Higher – Time to Buy?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock price rose 5.3% during trading on Tuesday . The stock traded as high as $22.95 and last traded at $22.6940. Approximately 1,206,498 shares changed hands during mid-day trading, a decline of 80% from the average daily volume of 6,042,610 shares. The stock had previously closed at $21.55.

Wall Street Analyst Weigh In

SRPT has been the subject of a number of analyst reports. Wedbush began coverage on shares of Sarepta Therapeutics in a research report on Tuesday, December 9th. They issued an “outperform” rating and a $32.00 price objective for the company. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a research note on Monday, August 25th. BMO Capital Markets raised Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $50.00 target price on the stock in a research report on Monday, September 22nd. Leerink Partners increased their target price on Sarepta Therapeutics from $12.00 to $15.00 and gave the company a “market perform” rating in a research note on Tuesday, September 9th. Finally, Robert W. Baird cut their price target on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating on the stock in a report on Tuesday, November 4th. Nine equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $33.68.

Sarepta Therapeutics Stock Performance

The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The stock’s 50-day moving average price is $20.78 and its 200 day moving average price is $20.64. The company has a market cap of $2.13 billion, a P/E ratio of -6.76 and a beta of 0.54.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). The firm had revenue of $399.36 million during the quarter, compared to the consensus estimate of $331.51 million. Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.Sarepta Therapeutics’s revenue was down 14.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.62 EPS. As a group, research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the sale, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at approximately $4,312,523. The trade was a 6.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 7.60% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Sarepta Therapeutics by 18.1% during the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after purchasing an additional 1,657,267 shares during the period. Erste Asset Management GmbH boosted its position in Sarepta Therapeutics by 65.7% in the third quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock valued at $50,588,000 after buying an additional 1,064,530 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Sarepta Therapeutics by 27.9% during the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock valued at $168,907,000 after purchasing an additional 577,848 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in shares of Sarepta Therapeutics by 2.1% in the first quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company’s stock valued at $127,512,000 after buying an additional 41,408 shares during the period. Finally, Aberdeen Group plc lifted its position in shares of Sarepta Therapeutics by 59.6% in the 3rd quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company’s stock worth $38,208,000 after purchasing an additional 740,360 shares during the period. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.